<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nitric oxide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nitric oxide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nitric oxide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9447" href="/d/html/9447.html" rel="external">see "Nitric oxide: Drug information"</a> and <a class="drug drug_patient" data-topicid="12266" href="/d/html/12266.html" rel="external">see "Nitric oxide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56048256"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Genosyl;</li>
<li>Inomax;</li>
<li>Noxivent</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867697"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Kinox;</li>
<li>Noxivent</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1027922"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Vasodilator, Pulmonary</span></li></ul></div>
<div class="block don drugH1Div" id="F53462521"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5f47bd76-0c4f-4884-b283-3e4f4a5461fe">Hypoxic respiratory failure associated with pulmonary hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoxic respiratory failure associated with pulmonary hypertension:</b> Neonates &gt;34 weeks gestational age: Inhalation: 20 parts per million (ppm); maintain treatment up to 14 days or until resolution of oxygen desaturation; doses &gt;20 ppm are not recommended due to risk of methemoglobinemia and pulmonary injury from elevated nitrogen dioxide (NO<sub>2</sub>). Abrupt discontinuation may lead to worsening oxygenation and rebound pulmonary hypertension; to avoid rebound wean nitric oxide. To wean nitric oxide, titrate down in several steps (pause several hours at each step); monitor for hypoxemia. Various weaning methods have been used in clinical trials and no standard wean exists; some have suggested weaning by 5 to 10 ppm every 4 hours until the patient is stable at 5 ppm; once stable at 5 ppm, the dose should be decreased by 1 ppm every 4 hours and discontinued at 1 ppm if the patient remains well oxygenated. If deterioration occurs during weaning or after discontinuation, increase nitric oxide to the previous dose or restart; once improved, wean more slowly (Peliowski 2012; Ware 2015). <b>Note:</b> Use in preterm neonates is not recommended; nitric oxide therapy does not improve survival in preterm neonates (&lt;34 weeks) with respiratory failure and evidence does not support using in these patients to prevent BPD, severe IVH, or other neonatal morbidities (AAP [Kumar 2014]).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment in renal impairment: </b> There are no dosage adjustments provided in manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment in hepatic impairment: </b> There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F7730323"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9447" href="/d/html/9447.html" rel="external">see "Nitric oxide: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c0942e9d-43b7-4cbd-a1db-c41b17d28d52">Acute respiratory distress syndrome, moderate to severe, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute respiratory distress syndrome, moderate to severe, refractory (off-label use):</b>
<b>Note:</b> Routine use is not recommended due to lack of impact on clinical outcomes (mortality, length of stay, mechanical ventilation duration) and a possible increased risk of kidney injury. However, may be used as rescue therapy to improve oxygenation if nonpharmacologic measures are ineffective. Based on limited data; optimal dosing strategy and titration remains unknown; refer to institutional policies and procedures (Adhikari 2014; Dzierba 2014; Gebistorf 2016; Griffiths 2019; Ruan 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Inhalation:</b> Initial dose: 5 to 10 parts per million (ppm); titrate to lowest effective dose based on clinical response and tolerability; usual dosage range: 1.25 to 40 ppm (Adhikari 2014; Dzierba 2014; Taylor 2004).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58a3cd23-4fbc-4ca7-8c74-26fd785e3679">Acute vasodilator testing in patients with pulmonary arterial hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute vasodilator testing in patients with pulmonary arterial hypertension (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Acute vasodilator testing is recommended in patients with idiopathic, heritable, or drug-induced pulmonary arterial hypertension to assess eligibility for treatment with a calcium channel blocker (eg, ER nifedipine) (ACCF/AHA [McLaughlin 2009]; ESC/ERS [Humbert 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Inhalation: </b>Usual dosage range: 10 to 80 ppm for 5 to 10 minutes while measuring hemodynamic response; may discontinue without weaning (ACC/AHA [McLaughlin 2009]; ESC/ERS [Humbert 2022]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7afcf987-a973-46bf-a4ee-5c986951da4f">Right ventricular dysfunction after cardiac surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Right ventricular dysfunction after cardiac surgery (off-label use):</b>
<b>Inhalation:</b> Usual dose: 20 ppm via mechanical ventilation circuit; dosage range: 5 to 20 ppm (Argenziano 1998; Costanzo 2010; Mosquera 2002; Paniagua 1999).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991992"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50989228"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F201921"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Cardiovascular: Hypotension (14%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased pulmonary artery pressure (with abrupt discontinuation)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Methemoglobinemia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hypoxemia (with abrupt discontinuation)</p></div>
<div class="block coi drugH1Div" id="F201934"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Neonates dependent on right-to-left shunting of blood</p></div>
<div class="block war drugH1Div" id="F201918"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Airway injury: May result from inflammation and lung tissue damage caused by nitrogen dioxide (NO<sub>2</sub>) formed in nitric oxide and oxygen gas mixtures. If there is an unexpected change in NO<sub>2</sub> concentration, or if NO<sub>2</sub> concentration in the breathing circuit reaches the manufacturer-recommended maximum ppm, assess delivery system and recalibrate the NO<sub>2</sub> analyzer; adjust dose of nitric oxide and/or FiO<sub>2</sub> as appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: Dose-related methemoglobin (when nitric oxide combines with hemoglobin) may occur and lead to hypoxemia; monitor methemoglobin concentrations within 4 to 8 hours of starting nitric oxide treatment and then periodically; optimize oxygenation by adjusting nitric oxide dose as necessary. If methemoglobin levels do not resolve with decrease in dose or discontinuation of nitric oxide, additional therapy may be warranted.</p>
<p style="text-indent:-2em;margin-left:4em;">• Platelet dysfunction: Inhaled nitric oxide may decrease platelet aggregation and agglutination without any impact on bleeding times. Although clinical trials have not observed any significant increases in bleeding rates associated with inhaled nitric oxide, patients with bleeding risk factors should be monitored closely (Dzierba 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal dysfunction: Inhaled nitric oxide may increase the risk of kidney injury. Although the exact mechanism remains unknown, inhaled nitric oxide may negatively impair the function of mitochondria and deoxyribonucleic acid as well as other various enzymes leading to renal failure (Gebistorf 2016; Ruan 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Use in patients with left ventricular dysfunction may increase pulmonary capillary wedge pressure, worsen left ventricular dysfunction, and cause pulmonary edema, systemic hypotension, bradycardia, and cardiac arrest; discontinue nitric oxide and provide symptomatic care.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary artery hypertension: Acute vasodilator testing (not an approved use): Use with extreme caution in patients with concomitant heart failure (LV systolic dysfunction with significantly elevated left heart filling pressures) or pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis; significant decompensation has occurred resulting in acute pulmonary edema.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abrupt discontinuation: Avoid abrupt discontinuation; may lead to worsening oxygenation, and increasing pulmonary artery pressure (PAP) (ie, rebound pulmonary hypertension syndrome). Signs and symptoms of rebound pulmonary hypertension syndrome include hypoxemia, systemic hypotension, bradycardia, and reduced cardiac output; reinitiate nitric oxide immediately if this occurs. In order to wean, titrate down in many steps (pause several hours at each step) and monitor for hypoxemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Doses above 20 ppm should not be used (or should be used with caution [off-label dosing]) because of the increased risk of methemoglobinemia and elevated levels of NO<sub>2</sub>, a toxic metabolite. Methemoglobin concentrations and inspired NO<sub>2</sub> should be monitored.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lack of response: Worsening oxygenation and increasing PAP may occur in patients who do not respond.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878564"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Elevations in methemoglobin and nitrogen dioxide may be signs of overdose. Elevated nitrogen dioxide may cause acute lung injury and elevations of methemoglobin reduce the oxygen delivery capacity of the circulation. NO<sub>2</sub> levels &gt;3 ppm or methemoglobin levels &gt;7% were treated by reducing the dose of or discontinuing nitric oxide. Methemoglobinemia that does not resolve with dosage reduction or discontinuation of therapy may require intravenous vitamin C, intravenous methylene blue, or blood transfusion, depending on the clinical situation.</p>
<p style="text-indent:0em;margin-top:2em;">Use in premature neonates (GA ≤34 weeks) is not recommended based on data from trials and meta-analysis. Nitric oxide (rescue and routine use for respiratory failure) did not improve survival nor was it found effective in the prevention or amelioration of bronchopulmonary dysplasia (AAP [Kumar 2014]).</p></div>
<div class="block foc drugH1Div" id="F56048257"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Gas, Inhalation:</p>
<p style="text-indent:-2em;margin-left:4em;">Genosyl Delivery System: Cassettes produce ≥216 liters of 800 ppm nitric oxide gas (at standard temperature and pressure)</p>
<p style="text-indent:-2em;margin-left:4em;">Inomax: 0.08% (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;">Noxivent: 0.01% (1 ea); 0.08% (1 ea)</p></div>
<div class="block geq drugH1Div" id="F201914"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block dinfoc drugH1Div" id="F52867698"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Gas, Inhalation:</p>
<p style="text-indent:-2em;margin-left:4em;">Kinox: 0.01% (1 ea); 0.08% (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;">Noxivent: 0.08% (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52613430"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Inhalation: Administration of nitric oxide should be done by a health care professional who has completed a comprehensive periodic training program. May only be administered using a calibrated delivery system with validated ventilator systems. To prevent treatment interruptions due to power and/or system failures, immediate access to a backup battery power supply and an independent reserve nitric oxide delivery system is essential. Do not abruptly discontinue; must wean. To wean nitric oxide, titrate down in several steps, pausing several hours before reducing further; monitor for hypoxemia.</p></div>
<div class="block adm drugH1Div" id="F201931"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Inhalation:</b> Administration of nitric oxide should be done by a health care professional who has completed a comprehensive training program, and may only be administered using a calibrated delivery system with validated ventilator systems. To prevent treatment interruptions (power and system failures), immediate access to a backup battery power supply and an independent reserve nitric oxide delivery system is essential. Do not abruptly discontinue; must wean. To wean nitric oxide, titrate down in several steps, pausing several hours before reducing further; monitor for hypoxemia.</p></div>
<div class="block sts drugH1Div" id="F201943"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store cylinders at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Adhere to all regulations related to storing pressurized vessels. Protect cylinders from shocks, falls, oxidizing and flammable materials, moisture, and sources of heat or ignition.</p>
<p style="text-indent:0em;margin-top:2em;">The exposure limit set by the Occupational Safety and Health Administration for nitric oxide is 25 ppm, and for NO<sub>2</sub> the limit is 5 ppm.</p></div>
<div class="block usep drugH1Div" id="F53568042"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension used in conjunction with ventilator support and other agents to improve oxygenation and reduce the need for extracorporeal membrane oxygenation (FDA approved for term and near-term [&gt;34 weeks gestational age] neonates)</p></div>
<div class="block cyt drugH1Div" id="F13299766"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F201923"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobinemia Associated Agents: Nitric Oxide may enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F56591951"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Although the risk of adverse outcomes is increased in pregnant patients with pulmonary arterial hypertension (PAH), data specific to the diagnostic or therapeutic use of nitric oxide in pregnancy are limited. Use of inhaled nitric oxide for acute vasodilator testing has been described in a pregnant patient with PAH (Mojoli 2006). Inhaled nitric oxide may be used to improve pulmonary blood flow and oxygenation in pregnant patients with PAH who also have cardiac decompensation (AHA [Canobbio 2017]; Ballard 2021; Hemnes 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Use of inhaled nitric oxide has been described for the treatment of severe COVID-19 pneumonia during pregnancy, and severe acute respiratory distress syndrome (ARDS) in pregnant or postpartum patients with or without COVID-19 (Garcha 2020; Mehrotra 2017; Palmrich 2021; Paramanathan 2021; Safaee Fakhr 2020; Valsecchi 2022); however, use of inhaled nitric oxide is not recommended for the routine treatment of severe ARDS in patients with COVID-19; nitric oxide may be considered as rescue therapy when other options have failed (NIH 2022).</p></div>
<div class="block mopp drugH1Div" id="F53568032"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Respiratory status including arterial blood gases with close attention to PaO<sub>2</sub>, methemoglobin (measured within 4 to 8 hours after initiation and periodically throughout treatment with nitric oxide), inspired NO<sub>2</sub>, vital signs</p></div>
<div class="block pha drugH1Div" id="F201917"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">In neonates with persistent pulmonary hypertension, nitric oxide improves oxygenation. Nitric oxide relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine 3',5'-monophosphate, which leads to vasodilation. When inhaled, pulmonary vasodilation occurs and an increase in the partial pressure of arterial oxygen results. Dilation of pulmonary vessels in well ventilated lung areas redistributes blood flow away from lung areas where ventilation/perfusion ratios are poor.</p></div>
<div class="block phk drugH1Div" id="F201933"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Systemic after inhalation </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Nitric oxide combines with hemoglobin that is 60% to 100% oxygenated. Nitric oxide combines with oxyhemoglobin to produce methemoglobin and nitrate. Within the pulmonary system, nitric oxide can combine with oxygen and water to produce nitrogen dioxide and nitrite respectively, which interact with oxyhemoglobin to then produce methemoglobin and nitrate. At 80 ppm the methemoglobin percent is ~5% in neonates after 8 hours of administration; methemoglobin levels &gt;7% were attained only in neonates receiving 80 ppm. Doses &gt;20 ppm are not recommended for use in neonatal patients.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F201939"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Inomax | Neophyr | Noxap | VasoKINOX</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Inoflo | Noxap | Oxido nitroso | Pulmonox</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Inomax | Noxap | Oxid dusnaty messer</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Inomax</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Inomax | VasoKINOX</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Inomax</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Inomax</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Neophyr</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">I&amp;o max breezhaler gas</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Inomax</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Inomax</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Inomax</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11853194">
<a name="11853194"></a>Akçay F, Aksoy H, Memisoğullari R. Effect of breast-feeding on concentration of nitric oxide in breast milk. <i>Ann Clin Biochem</i>. 2002;39(pt 1):68-69. doi:10.1258/0004563021901595<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/11853194/pubmed" id="11853194" target="_blank">11853194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24132038">
<a name="24132038"></a>Adhikari NK, Dellinger RP, Lundin S, et al. Inhaled nitric oxide does not reduce mortality in patients with acute respiratory distress syndrome regardless of severity: systematic review and meta-analysis. <i>Crit Care Med</i>. 2014;42(2):404-412. doi:10.1097/CCM.0b013e3182a27909<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/24132038/pubmed" id="24132038" target="_blank">24132038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9485226">
<a name="9485226"></a>Argenziano M, Choudhri AF, Moazami N, et al. Randomized, Double-Blind Trial of Inhaled Nitric Oxide in LVAD Recipients With Pulmonary Hypertension. <i>Ann Thorac Surg.</i> 1998;65(2):340-345.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/9485226/pubmed" id="9485226" target="_blank">9485226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33222807">
<a name="33222807"></a>Ballard W 3rd, Dixon B, McEvoy CA, Verma AK. Pulmonary arterial hypertension in pregnancy. <i>Cardiol Clin</i>. 2021;39(1):109-118. doi:10.1016/j.ccl.2020.09.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/33222807/pubmed" id="33222807" target="_blank">33222807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28082385">
<a name="28082385"></a>Canobbio MM, Warnes CA, Aboulhosn J, et al; American Heart Association Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Functional Genomics and Translational Biology; and Council on Quality of Care and Outcomes Research. Management of pregnancy in patients with complex congenital heart disease: a scientific statement for healthcare professionals from the American Heart Association. <i>Circulation</i>. 2017;135(8):e50-e87. doi:10.1161/CIR.0000000000000458<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/28082385/pubmed" id="28082385" target="_blank">28082385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20643330">
<a name="20643330"></a>Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the Care of Heart Transplant Recipients. <i>J Heart Lung Transplant.</i> 2010;29(8):914-956.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/20643330/pubmed" id="20643330" target="_blank">20643330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9428538">
<a name="9428538"></a>Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled nitric oxide in ARDS Study Group. <i>Crit Care Med</i>. 1998;26(1):15-23. doi:10.1097/00003246-199801000-00011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/9428538/pubmed" id="9428538" target="_blank">9428538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24734313">
<a name="24734313"></a>Dzierba AL, Abel EE, Buckley MS, Lat I. A review of inhaled nitric oxide and aerosolized epoprostenol in acute lung injury or acute respiratory distress syndrome. <i>Pharmacotherapy</i>. 2014;34(3):279-290. doi:10.1002/phar.1365<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/24734313/pubmed" id="24734313" target="_blank">24734313</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Garcha G, Howe C. Use of inhaled nitric oxide for ARDS in pregnancy. <i>Chest</i>. 158(4):A981 doi:10.1016/j.chest.2020.08.912</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27347773">
<a name="27347773"></a>Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. <i>Cochrane Database Syst Rev.</i> 2016;(6):CD002787. doi:10.1002/14651858.CD002787.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/27347773/pubmed" id="27347773" target="_blank">27347773</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Genosyl (nitric oxide) [prescribing information]. Atlanta, GA: Vero Biotech; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31258917">
<a name="31258917"></a>Griffiths MJD, McAuley DF, Perkins GD, et al. Guidelines on the management of acute respiratory distress syndrome. <i>BMJ Open Respir Res.</i> 2019;6(1):e000420. doi:10.1136/bmjresp-2019-000420<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/31258917/pubmed" id="31258917" target="_blank">31258917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26401246">
<a name="26401246"></a>Hemnes AR, Kiely DG, Cockrill BA, et al. Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. <i>Pulm Circ</i>. 2015;5(3):435-465. doi:10.1086/682230<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/26401246/pubmed" id="26401246" target="_blank">26401246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20958096">
<a name="20958096"></a>Hord NG, Ghannam JS, Garg HK, Berens PD, Bryan NS. Nitrate and nitrite content of human, formula, bovine, and soy milks: implications for dietary nitrite and nitrate recommendations. <i>Breastfeed Med</i>. 2011;6(6):393-399. doi:10.1089/bfm.2010.0070<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/20958096/pubmed" id="20958096" target="_blank">20958096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017548">
<a name="36017548"></a>Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.<i> Eur Heart J</i>. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/36017548/pubmed" id="36017548" target="_blank">36017548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-INOmax.1">
<a name="INOmax.1"></a>INOmax (nitric oxide) [prescribing information]. Bedminster, NJ: INO Therapeutics LLC; January 2023.</div>
</li>
<li>
<div class="reference">
                  INOmax (nitric oxide) [product monograph]. Ontario, Canada: Mallinckrodt Manufacturing; October 2017.</div>
</li>
<li>
<div class="reference">
                  Kinox (nitric oxide) [product monograph]. Brampton, Ontario, Canada: VitalAire Canada Inc; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24379225">
<a name="24379225"></a>Kumar P; Committee on Fetus and Newborn; American Academy of Pediatrics. Use of inhaled nitric oxide in preterm infants. <i>Pediatrics</i>. 2014;133(1):164-170. doi: 10.1542/peds.2013-3444.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/24379225/pubmed" id="24379225" target="_blank">24379225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19332472">
<a name="19332472"></a>McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. <i>Circulation.</i> 2009;119(16):2250-2294. doi:10.1161/CIRCULATIONAHA.109.192230<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/19332472/pubmed" id="19332472" target="_blank">19332472</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mehrotra A, Lanfranco JM, Rombero-Legro I, et al. Novel use of inhaled nitric oxide as salvage therapy for peripartum acute respiratory distress during cesarean section. <i>Am J Respir Crit Care Med</i>. 2017;195:A5885</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16922775">
<a name="16922775"></a>Mojoli F, Zanierato M, Campana C, Braschi A. Inhaled nitric oxide test in a pregnant patient with severe pulmonary hypertension. <i>Anaesthesia</i>. 2006;61(9):912. doi:10.1111/j.1365-2044.2006.04769.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/16922775/pubmed" id="16922775" target="_blank">16922775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11959233">
<a name="11959233"></a>Mosquera I, Crespo-Leiro MG, Tabuyo T, et al. Pulmonary Hypertension and Right Ventricular Failure After Heart Transplantation: Usefulness of Nitric Oxide. <i>Transplant Proc.</i> 2002;34(1):166-167.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/11959233/pubmed" id="11959233" target="_blank">11959233</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. <a href="https://www.covid19treatmentguidelines.nih.gov/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/</a>. Updated October 19, 2022. Accessed October 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9036320">
<a name="9036320"></a>Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. <i>N Engl J Med</i>. 1997 Feb 27;336(9):597-604. doi: 10.1056/NEJM199702273360901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/9036320/pubmed" id="9036320" target="_blank">9036320</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Noxivent (nitric oxide) [prescribing information]. Danbury, CT: Praxair Distribution, Inc; January 2019.</div>
</li>
<li>
<div class="reference">
                  Noxivent (nitric oxide) [product monograph]. Mississauga, Ontario, Canada: Praxair Canada Inc; January 2016.</div>
</li>
<li>
<div class="reference">
                  Palmrich P, Roessler B, Wisgrill L, et al. Multiprofessional perinatal care in a pregnant patient with acute respiratory distress syndrome due to COVID-19. <i>BMC Pregnancy Childbirth</i>. 2021;21(1):587. doi:10.1186/s12884-021-04059-y</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10500690">
<a name="10500690"></a>Paniagua MJ, Crespo-Leiro MG, Rodríguez JA, et al. Usefulness of Nitric Oxide Inhalation for Management of Right Ventricular Failure After Heart Transplantation in Patients With Pretransplant Pulmonary Hypertension. <i>Transplant Proc. </i>1999;31(6):2505-2506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/10500690/pubmed" id="10500690" target="_blank">10500690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33718007">
<a name="33718007"></a>Paramanathan S, Kyng KJ, Laursen AL, Jensen LD, Grejs AM, Jain D. COVID-19 with severe acute respiratory distress in a pregnant woman leading to preterm caesarean section: a case report. <i>Case Rep Womens Health</i>. 2021;30:e00304. doi:10.1016/j.crwh.2021.e00304<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/33718007/pubmed" id="33718007" target="_blank">33718007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31197492">
<a name="31197492"></a>Papazian L, Aubron C, Brochard L, et al. Formal guidelines: management of acute respiratory distress syndrome. <i>Ann Intensive Care</i>. 2019;9(1):69. doi:10.1186/s13613-019-0540-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/31197492/pubmed" id="31197492" target="_blank">31197492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25887847">
<a name="25887847"></a>Ruan SY, Huang TM, Wu HY, Wu HD, Yu CJ, Lai MS. Inhaled nitric oxide therapy and risk of renal dysfunction: a systematic review and meta-analysis of randomized trials.<i> Crit Care.</i> 2015;19:137. doi:10.1186/s13054-015-0880-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/25887847/pubmed" id="25887847" target="_blank">25887847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32852324">
<a name="32852324"></a>Safaee Fakhr B, Wiegand SB, Pinciroli R, et al. High concentrations of nitric oxide inhalation therapy in pregnant patients with severe Coronavirus Disease 2019 (COVID-19). <i>Obstet Gynecol</i>. 2020;136(6):1109-1113. doi:10.1097/AOG.0000000000004128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/32852324/pubmed" id="32852324" target="_blank">32852324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15069048">
<a name="15069048"></a>Taylor RW, Zimmerman JL, Dellinger RP, et al; Inhaled Nitric Oxide in ARDS Study Group. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. <i>JAMA</i>. 2004;291(13):1603-1609. doi:10.1001/jama.291.13.1603<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/15069048/pubmed" id="15069048" target="_blank">15069048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35852269">
<a name="35852269"></a>Valsecchi C, Winterton D, Safaee Fakhr B, et al; DELiverly oF iNO (DELFiNO) Network Collaborators. High-dose inhaled nitric oxide for the treatment of spontaneously breathing pregnant patients with severe coronavirus disease 2019 (COVID-19) pneumonia. <i>Obstet Gynecol</i>. 2022;140(2):195-203. doi:10.1097/AOG.0000000000004847<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/35852269/pubmed" id="35852269" target="_blank">35852269</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 106992 Version 90.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
